news
Immunotherapy: antibody set for combating tumours
A recent study sheds light on the potential of artificial DNA structures that, when combined with antibodies, guide the immune system to target cancer cells specifically.
List view / Grid view
Cancer
article
Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance
In this interview with Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm, we discover research uncovering a central factor contributing to anti-PD-1 resistance in cancer immunotherapy.
news
DNA repair breakthroughs for innovative cancer treatment
This study explores cell survival, the continuous repair of DNA breaks is crucial. Failure to repair DNA effectively can result in mutations, contributing to the development of cancer.
article
HPV-associated head and neck cancers identified
Human papillomavirus (HPV)-associated head and neck cancers, specifically head and neck squamous cell carcinoma (HNSCC), are on the rise worldwide. Yet, the factors contributing to these tumours and their varying responses to treatment remain poorly understood.
article
The potential of FcγRIIB in immunotherapy
We exclusively interview Dr Ali Roghanian, Associate Professor at the University of Southampton, UK, Ali is a leading researcher at the forefront of immunotherapy advancements. With a keen focus on the inhibitory IgG FcγRIIB receptor, join us as we dive into Ali’s findings, showcasing the complexities of FcγRIIB and its…
article
SERS-artificial intelligence method for early detection of cancer
Scientists have developed a promising new method to detect cancer at very early stages during routine health screens, paving way for improved treatment and recovery.
article
Ageing and cancer-causing gene: researchers uncover a link
Researchers from UPMC Children's Hospital of Pittsburgh and the University of Pittsburgh School of Medicine have made a discovery linking the notorious cancer-causing gene, Myc, to the process of ageing.
article
Cancer metastasis: breakthrough in therapeutic strategies
A new discovery from the University of Southern California (USC) on cancer metastasis has opened up new possibilities for combating the spread of this devastating disease.
podcasts
Episode 21 – Allogeneic cell therapies and the immune system
This episode defines allogeneic cell therapy as the administration of cells to a patient for therapeutic use, that were not initially taken from that patient.
news
Cracking the code of influenza evolution
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
news
Harnessing machine learning for early cancer detection in primary care
Machine learning (ML) presents a promising opportunity to revolutionize early cancer detection in primary care, addressing the challenges associated with diagnostic errors and improving patient outcomes. The potential of ML in this field is highlighted in a recent paper published in Oncoscience
news
Specialised white blood cells could lead to more preventative treatments
Australian researchers analyse the way specialised white blood cells produce an immune response, which could lead to the development of preventative treatments for cancer and infectious diseases.
article
Biochemical assays and deep cyclic inhibition in cancer treatment
Drug Target Review's Taylor Mixides exclusively interviews Brett Hall, Chief Scientific Officer at Immuneering, about his company’s aim to develop a universal-RAS therapy.
article
The promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
article
Antibody Drug Conjugates: windows of opportunity
This articles aims to drive understanding in Antibody Drug Conjugate (ADC) drug development to improve patient outcomes. Petra Dieterich, Ian Glassford, and Jeff Mocny, Scientific Leaders at Abzena discuss real-world data that is challenging traditional scientific thinking on the ADC therapeutic window. The authors also explore the need for further…